Skip to Main content Skip to Navigation
Journal articles

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

Carolyn Lam 1, 2 João Ferreira 3, 4, 5, 6 Egon Pfarr 7 David Sim 1 Hiroyuki Tsutsui 8, 9 Stefan Anker 10, 11, 12 Javed Butler 13 Gerasimos Filippatos 14, 15 Stuart Pocock 16 Naveed Sattar 17 Subodh Verma 18, 19 Martina Brueckmann 7, 20 Janet Schnee 21 Daniel Cotton 21 Faiez Zannad 3, 4, 5, 6 Milton Packer 22, 23
Abstract : Abstract Aims The aim of this article is to explore the influence of region and race/ethnicity on the effects of empagliflozin in the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) trial. Methods and results Of 3730 patients, 1353 (36.3%) were enrolled in Europe, 1286 (34.5%) in Latin America, 425 (11.4%) in North America, and 493 (13.2%) in Asia; 2629 (70.5%) were White, 257 (6.9%) Black, and 672 (18.0%) Asian. Placebo event rates (per 100 patient-years) for cardiovascular death or heart failure (HF) hospitalization varied by region (Asia 27.7, North America 26.4, Latin America 21.4, and Europe 17.5) and race/ethnicity (Black 34.4, Asian 24.3, and White 18.7); driven by differences in HF hospitalization. The ratio of total HF hospitalization to cardiovascular death varied from 5.4 in Asia and 4.8 in North America to 2.1 in Europe; and from 4.8 in Black and 4.2 in Asian to 2.2 in White patients. Groups with the highest ratio had the greatest reduction in the primary outcome with empagliflozin. Inclusion of outpatient worsening HF episodes added more events in Europe vs. other regions; enhanced the placebo event rates in Europe vs. other regions; and increased the relative risk reduction with empagliflozin in Europe from 6% to 26%. Conclusions There were notable differences in the placebo event rates for major HF events across diverse regions and race/ethnic groups. The benefit of empagliflozin was most pronounced in groups with the highest ratio of HF hospitalization to cardiovascular death. Regional differences were attenuated when the definition of HF events was expanded to include outpatient worsening HF events.
Complete list of metadata

https://hal.univ-lorraine.fr/hal-03276122
Contributor : Erwan Bozec <>
Submitted on : Thursday, July 1, 2021 - 5:01:16 PM
Last modification on : Saturday, August 21, 2021 - 3:08:08 AM

File

ehab360.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Carolyn Lam, João Ferreira, Egon Pfarr, David Sim, Hiroyuki Tsutsui, et al.. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, Oxford University Press (OUP): Policy B, 2021, pp.ehab360. ⟨10.1093/eurheartj/ehab360⟩. ⟨hal-03276122⟩

Share

Metrics

Record views

29

Files downloads

49